Venlafaxine Hydrochloride Capsule, Extended Release
Product Images NDC 70518-4151

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Venlafaxine Hydrochloride (NDC 70518-4151). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Remedyrepack Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Remedy_label (Remedy Label)

Label for Venlafaxine Hydrochloride 75 mg extended-release oral capsules. The label indicates a quantity of 30 capsules, repackaged by RemedyRepack Inc. It includes the NDC 70518-4151-00 and manufacturing information for Epic Pharma, LLC. Storage instructions and a note to see the package insert for directions are also present.*

FDA Label Image

Image-01 (Image 01)

Chemical structure diagram of venlafaxine hydrochloride showing its molecular components and arrangement, including a cyclohexane ring, aromatic ring with a methoxy group, and a dimethylamino group attached to the central carbon atom.*

FDA Label Image

Image-02 (Image 02)

A scatter plot chart showing the fold change and 90% confidence interval for venlafaxine and its O-desmethylvenlafaxine (ODV) metabolite across various special populations, including hepatic impairment (cirrhosis, mild, moderate), renal impairment (mild/moderate, hemodialysis), CYP2D6 polymorphism, age over 60 years, and gender (female/male). The x-axis represents the change relative to the reference value, ranging from 0 to 3.5, and data points represent Cmax and AUC pharmacokinetic parameters.*

FDA Label Image

Image-03 (Image 03)

A scatter plot chart illustrating the fold change and 90% confidence intervals (CI) of pharmacokinetic parameters (Cmax and AUC) for venlafaxine and ODV analytes when co-administered with various interacting drugs. The x-axis shows the change relative to the reference value, and the interacting drugs include ethanol, diazepam, cimetidine, ketoconazole (in CYP2D6 EM's and PM's), indinavir, metoprolol, imipramine, and lithium.*

FDA Label Image

Image-04 (Image 04)

A scatter plot chart presenting the fold change with 90% confidence intervals for various interacting drugs and analytes affecting pharmacokinetic parameters Cmax and AUC. The chart compares these values relative to a reference, covering drugs including ethanol, diazepam, alprazolam, indinavir, metoprolol, risperidone, imipramine, haloperidol, caffeine, tolbutamide, and lithium.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.